The estimated Net Worth of Priya Singhal is at least $263 Тысяча dollars as of 30 August 2024. Priya Singhal owns over 1,668 units of Zafgen stock worth over $6,488 and over the last 6 years he sold ZFGN stock worth over $256,391. In addition, he makes $0 as Head of Research and Development at Zafgen.
Priya has made over 14 trades of the Zafgen stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 1,668 units of ZFGN stock worth $1,651 on 30 August 2024.
The largest trade he's ever made was exercising 1,828 units of Zafgen stock on 1 February 2024 worth over $1,810. On average, Priya trades about 595 units every 30 days since 2019. As of 30 August 2024 he still owns at least 6,554 units of Zafgen stock.
You can see the complete history of Priya Singhal stock trades at the bottom of the page.
Dr. Priya Singhal, M.D., M.P.H., is the Head of Research and Development of the Company. Dr. Singhal joined Zafgen in March 2019. Dr. Singhal brings more than a decade of experience as a senior drug development executive and several years of experience as a clinician to her role as Head of Research and Development. She leads and oversees the Company’s research, clinical and manufacturing strategy and implementation and serves as a key member of the executive team supporting overall business strategy. Most recently, Dr. Singhal was concurrently the Senior Vice President and the Global Head of Safety and Benefit Risk Management (or SABR) and the Interim Global Co-lead and Senior Vice President of Global Development at Biogen Inc. Dr. Singhal led the worldwide benefit-risk strategy for the Biogen portfolio as well as for the filings and approvals of six products, including Tecfidera and Spinraza. She also contributed to Biogen’s overall research and development strategy and drug development plans, chaired safety governance for the entire portfolio, and led numerous successful portfolio and product interactions with regulators worldwide. Prior to Biogen, Dr. Singhal held roles of increasing seniority at Vertex Pharmaceuticals Incorporated, including Vice President, Medical Affairs, where she led strategy and educational efforts across all Vertex programs including the company’s hepatitis C (or HCV) and cystic fibrosis portfolios. She led benefit-risk for the HCV portfolio and represented Vertex at the FDA Advisory Committee for Incivek that resulted in an 18-0 positive vote. Previously, Dr. Singhal also led benefit-risk for Velcade and two compounds in the development portfolio at Millennium Pharmaceuticals, Inc. Dr. Singhal earned her M.P.H. at Harvard School of Public Health and M.D. (internal medicine) from the University of Mumbai.
Priya Singhal is 51, he's been the Head of Research and Development of Zafgen since 2019. There are 5 older and 2 younger executives at Zafgen. The oldest executive at Zafgen, Inc. is Thomas Daniel, 66, who is the Independent Director.
Over the last 10 years, insiders at Zafgen have traded over $14,218,922 worth of Zafgen stock and bought 689,531 units worth $3,998,442 . The most active insiders traders include James E Deerfield Mgmt L.P...., Bruce Booth и Kevin P Starr. On average, Zafgen executives and independent directors trade stock every 53 days with the average trade being worth of $87,516. The most recent stock trade was executed by Thomas E. Hughes on 28 June 2018, trading 32,000 units of ZFGN stock currently worth $320,000.
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
Zafgen executives and other stock owners filed with the SEC include: